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oRIGINAL ARTICLE
Objective: Expression of N-myc downstream-regulated gene 1 
(NDRG1)/Cap43 is a prognostic indicator of human malignancies 
according to the tumor type in which it occurs. We investigated how 
NDRG1/Cap43 could affect tumor growth and angiogenesis in non–
small-cell lung cancer (NSCLC) in vivo using an animal experi-
mental model, and also how it could affect tumor angiogenesis and 
prognosis in NSCLC patients.
Methods and Results: Knockdown of NDRG1/Cap43 in lung can-
cer cells using a specific small interfering RNA resulted in growth 
rates in culture that were similar to those of counterpart control cells, 
but decreased tumor growth rates in vivo markedly. Stable NDRG1/
Cap43 knockdown did not induce consistent changes in the expres-
sion of Epidermal growth factor receptor (EGFR) family proteins 
and c-Met in two human lung cancer cell lines in vitro. However, cell 
lines with NDRG1/Cap43 knockdown showed markedly decreased 
production of the potent angiogenic factors vascular endothe-
lial growth factor-A and interleukin-8. Cells with knockdown of 
NDRG1/Cap43 showed marked reduction of tumor-induced angio-
genesis. Using immunohistochemistry, we examined 182 surgically 
resected specimens of NSCLC for expression of NDRG1/Cap43 
and tumor angiogenesis. High microvessel density in the tumor was 
significantly associated with nuclear positivity for NDRG1/Cap43 
in both adenocarcinoma (p = 0.003) and squamous cell carcinoma 
(p=0.041). For both adenocarcinoma (p = 0.031) and squamous cell 
carcinoma (p=0.034), the survival curve of patients negative for 
nuclear NDRG1/Cap43 expression differed significantly from that of 
patients who were positive.
Conclusion: Therefore, the expression of NDRG1/Cap43 may be 
predictive of tumor angiogenesis and poor prognosis in NSCLC.
Key Words: NDRG1/Cap43, Non–small-cell lung cancer, Epidermal 
growth factor receptor, Immunohistochemistry, Angiogenesis.
(J Thorac Oncol. 2012;7: 779–789)
N-myc downstream-regulated gene 1 (NDRG1)/Cap43 has been identified as a nickel- and calcium–inducible 
gene,1,2 and is identical to both homocysteine-inducible gene 
reduced in tumor cells (RTP/rit42),3 and differentiation-
related gene-1(Drg-1).4 The expression of NDRG1/Cap43 is 
markedly influenced by various stimuli, including oxidative 
stress, metal ions, hypoxia, phorbol esters, vitamins A and 
D, steroids, homocysteine, and tunicamycin, and oncogenes 
(N-myc and C-Myc) and tumor suppressor genes (p53 and von 
Hippel-Lindau).1,3,5–9 NDRG1/Cap43 is expressed in various 
organs, including the prostate, ovary, colon, and kidney, and 
its expression changes dynamically during postnatal develop-
ment in the kidney, brain, liver, and nerves.5,10–12
our previous study demonstrated that overexpression 
of NDRG1/Cap43 markedly suppressed tumor angiogen-
esis and growth of human pancreatic cancer, and also that 
the level of NDRG1/Cap43 expression was significantly 
and inversely correlated with longer overall survival and 
tumor microvascular density (MVD) in patients with pan-
creatic cancer.13 In patients with breast and prostate cancer 
and patients with neuroblastoma, a low level of NDRG1/
Cap43 expression has reportedly been correlated with poor 
prognosis.14–16 In contrast, high NDRG1/Cap43 expression 
is related to poor prognosis and angiogenesis in cervical 
adenocarcinoma and gastric cancer.17,18 A related study has 
also shown that high NDRG1/Cap43 expression is corre-
lated with tumor differentiation, vascular invasion, and poor 
prognosis in patients with hepatocellular carcinoma.19 Thus 
it seems that whether high NDRG1/Cap43 expression sup-
presses tumor growth and angiogenesis depends upon the 
type of human malignancy.20
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Lung cancer continues to be the leading cause of cancer 
deaths worldwide.21 Non–small-cell lung cancer (NSCLC) is 
the most common type of lung cancer, accounting for approx-
imately 80% of cases. More than half of affected patients 
already have metastasis at the time of diagnosis, and chemo-
therapy is the most effective treatment. Although many clinical 
trials of platinum-based chemotherapy in combination with 
various drugs have been conducted, the median survival time 
of NSCLC patients remains poor. The overall 5-year survival 
is approximately 15%, and has improved only marginally over 
the last few decades despite progress in new anticancer thera-
peutic agents. Recent progress in novel therapeutics, including 
molecular targeting drugs, has improved therapeutic efficacy 
in some NSCLC patients.22–24 Furthermore, development of 
new agents for cancer therapy, including vascular endothelial 
growth factor (VEGF)-A–targeted drugs, is expected to bring 
further benefits to NSCLC patients.25 In the present study, we 
investigated whether NDRG1/Cap43 expression in lung can-
cer cells could affect the growth and angiogenesis of tumor 
xenografts in mice, and also whether NDRG1/Cap43 expres-
sion could affect the outcome of patients with NSCLC.
MATERIALS AND METHODS
Cells, Cell Culture, and Immunoblotting
Human lung cancer cells lines A549, PC9, 11_18, 
LK87, LC-1 (adenocarcinoma), QG56, LC-Sq-1, and RERF-
LC-AI (squamous cell carcinoma) were maintained in RPMI 
1640 supplemented with 10% fetal bovine serum (FBS) and 
incubated in a humidified atmosphere of 5% Co
2
 at 37°C. 
Anti-NDRG1/Cap43 antibodies were produced in our labo-
ratory.9,26 PC9 and QG56 cells were kindly provided by 
Dr.Yukito Ichinose (Kyushu Cancer Center, Fukuoka, Japan) 
and LK87, LC-1, LC-Sq-1, and RERF-LC-AI cells were 
kindly provided by Kyogo Itoh (Kurume University, Fukuoka, 
Japan). The rabbit polyclonal antibody against NDRG1/Cap43 
was used as described previously.13 Anti-EGFR antibody was 
obtained from Cell Signaling Technology (Beverly, MA), anti-
HER2 was purchased from Upstate, Inc. (Lake Placid, NY), 
anti-HER3 was obtained from Santa Cruz Biotechnology, 
Inc. (Santa Cruz, CA), anti-c-Met was obtained from IBL 
Laboratories (Gunma, Japan), and anti-beta-actin was pur-
chased from Sigma Aldrich (St. Louis, Mo).
Small Interfering RNA Transfection and 
Immunoblotting
Small interfering RNA (siRNA) corresponding to a 
nucleotide sequence of NDRG1/Cap43 (5-AAC GTG AAC 
CCT TGT GCG GAA-3) was purchased from QIAGEN Inc. 
(Valencia, CA). A negative control siRNA was obtained from 
Invitrogen (Carlsbad, CA). siRNA duplexes were transfected 
using LipofectAMINE RNAiMAX and opti-MEM medium 
(Invitrogen) in accordance with the manufacturer’s recom-
mendations. Seventy-two hours after siRNA transfection, the 
cells were lysed in cold protein extraction reagent (M-PER; 
Pierce) with both protease and phosphatase inhibitors. Cell 
lysates were subjected to sodium dodecyl sulfate-polyacrylam-
ide gel electrophoresis using NuPage 4% to 12% Bis-Tris gels 
(Invitrogen) in accordance with the manufacturer’s instructions, 
and Western blot analyses were performed using a standard 
protocol. After transfer, the blots were incubated with blocking 
solution and probed with antibodies. The intensity of the lumi-
nescence was quantified using a CCD camera combined with 
an image analysis system (LAS-4000; Fuji Film, Japan).
NDRG1 Knockdown Vector Construction and 
Transfection
Cap43 complementary DNA was amplified by reverse 
transcription-polymerase chain reaction using the 5and 
3primers 5-GATCCGCGTGAACCCTTGTGCGGAATTCA
AGAGATTCCGCACAAGGGTTCACGTTTTTTGGAA-3 
and 5-AGCTTTTCCAAAAAACGTGAACCCTTGTGCGG
AATCTCTT
GAATTCCGCACAAGGGTTCACGCG-3, respectively. 
The amplified Cap43 complementary DNA was then ligated 
into the pcDNA3_GFP_hU6siRNA 1.0 vector (Invitrogen, 
Carlsbad, CA) (pcDNA3-Cap43). Cells were transfected with 
pcDNA3-Cap43 or pcDNA3-Mock using LipofectAMINE 2000 
(Invitrogen) in accordance with the manufacturer’s protocol. 
Stable transfected clones were established using G418 selection.
Determination of VEGF and Ínterleukin-8 by 
ELISA
The concentrations of VEGF and interleukin-8 (IL-8) 
in the conditioned medium and tissue lysates were measured 
using commercially available enzyme-linked immunosorbent 
assay (ELISA) kits.13 Cells were plated in 24-well dishes in 
medium containing 10% FBS. When the cells reached subcon-
fluence, the medium was replaced with Dulbecco’s Modified 
Eagle Medium containing 2% FBS, and then the cells were 
incubated for another 24 hours. Results were normalized for 
the number of cells and expressed as picograms of growth fac-
tor/105 cells/24 hours. The concentrations of VEGF and IL-8 
in the lysate supernatants were measured using an ELISA kit 
in accordance with the manufacturer’s protocols.
Animals
All animal studies were done in accordance with the 
Recommendations for Handling of Laboratory Animals for 
Biomedical Research compiled by the Committee on Safety 
and Ethical Handling Regulations for Laboratory Animal 
Experiments, Kinki University, Higashiosaka, osaka, Japan. 
The ethical procedures followed met the requirements of 
the United Kingdom Coordinating Committee on Cancer 
Research guidelines.27 Male athymic nude mice were exposed 
to a 12-hour light, 12-hour dark cycle and provided with food 
and water ad libitum in a barrier facility.
Tumor cells were implanted subcutaneously into the right 
hind leg of individual 6-week-old female athymic nude mice 
(BALB/c nu/nu; CLEA Japan). Tumor volume was determined 
from caliper measurements of tumor length (L) and width (W) 
according to the formula LW2/2. Tumor size was measured twice 
per week. Animals were observed for signs of tumor growth, 
activity, feeding, and pain in accordance with the guidelines of 
the Harvard Medical Area Standing Committee on Animals.
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Nude Mouse Xenograft Models and 
Determination of MVD
Cells were suspended in sterile phosphate-buffered 
saline at a concentration of 108 cells/ml, and 100 AL were 
injected s.c. into the right flank of individual nude mice. 
Tumor size was measured using calipers across the largest 
diameter and perpendicular to it to calculate the tumor area. 
Intratumoral microvessels were detected using a rat anti-
mouse CD34 antibody as described previously.13 Tumors in 
nude mice were removed, snap-frozen in optimum cutting 
temperature compound (Sakura Fine Technical, Japan), and 
6-Am sections were cut, air-dried, and fixed in cold acetone 
for 10 minutes. The sections were blocked with 3% bovine 
serum albumin and labeled at room temperature with rat anti-
mouse CD34 for 1 hour, followed by biotinylated goat anti-
rat IgG for 20 minutes. Intratumoral microvessels in human 
specimens were detected using a monoclonal antibody against 
CD34 antigen (monoclonal mouse antihuman CD34 antibody; 
Nichirei, Tokyo, Japan). In all samples, the mean number of 
microvessels was calculated from four vascular hotspots, and 
assessed as the MVD for each case. only CD34 staining in 
the tumor area was reviewed, and any endothelial cell cluster 
consisting of two or more cells was considered to be a single, 
countable microvessel. All counts were done by three inde-
pendent observers without any knowledge of the correspond-
ing clinicopathologic data.
Mouse Dorsal Air sac Assay
A549/mock5 or A549/Cap9 cells (1 × 106 cells) were 
injected into a chamber that consisted of a ring (Micro 
Industries Co., Ltd., Tokyo, Japan), and implanted into an air 
sac as described previously.28 on day 5, the chambers were 
removed, and photographs of these sites were assessed, fol-
lowed by determination of newly formed vessels.
Patients and Tumor Samples
We examined 182 patients with primary NSLSC 
whose tumors had been completely removed surgically at the 
Department of Surgery, Kurume University, Kurume, Japan, 
between 1997 and 2005. Among the 182 patients, 115 were 
diagnosed histologically as having adenocarcinoma, and the 
other 67 were diagnosed as having squamous cell carcinoma. 
The age of the patients with NSCLC ranged from 41 to 82 
years (median, 64 years), 117 were men and, 65 were women. 
None of the patients had received neoadjuvant or adjuvant 
chemotherapy. The median follow-up period was 1511.5 days 
(range, 159 to 3801 d). The present study conforms to the pro-
visions of the Declaration of Helsinki, and was approved by 
the Institutional Review Board of Kurume University.
Immunohistochemistry
Paraffin-embedded tissue samples were cut at a thickness 
of 4 μm and examined on coated glass slides, after labeling 
with antibodies directed against NDRG1/Cap43 and CD34. 
For NDRG1/Cap43, the BenchMark XT was used (Ventana 
Automated Systems, Inc., Tucson, AZ). This automated sys-
tem employs the streptavidin-biotin complex method with 3,3’ 
diaminobenzidine as the chromogen (Ventana iVIEW DAB 
Detection Kit). Antigen retrieval of NDRG1/Cap43 was done 
by heat treatment in a CC1 (Ventana). CD34 antigen retrieval 
was done by treatment with Proteinase K for 5 minutes. 
Each slide was incubated overnight with the antibody at 4°C. 
For staining detection, the ChemMate ENVISIoN method 
(DakoCytomation, Glostrup, Denmark) was used with 3,3’ 
diaminobenzidine as the chromogen.
Evaluation of Immunohistochemistry
The expression of NDRG1/Cap43 protein in the cyto-
plasm and nucleus was investigated in detail. Cytoplasmic 
NDRG1/Cap43 expression was classified into three categories: 
score 0, no staining at all, or faint/barely perceptible partial 
membrane expression in less than 10% of cancer cells; score 
1+, weak–to-moderate expression on the entire membrane in 
more than 10% of the cancer cells; score 2+, strong expression 
on the entire membrane in more than 10% of cancer cells. 
Nuclear NDRG1/Cap43 expression was classified into three 
categories: score 0, no staining at all; score 1+, nuclear expres-
sion in less than 10% of the cancer cells; score 2+, nuclear 
expression in more than 0% of the cancer cells. The extent of 
immunohistochemistry (IHC) for NDRG1/Cap43 was defined 
as follows: a score of 2+ was regarded as positive, and a score 
of 0 or 1 as negative. All IHC studies were evaluated by two 
IHC-experienced reviewers who were blind to the conditions 
of the patients (M. Kage and A.K).
MVD Analysis
MVD analysis was performed to measure the area of 
CD34 expression in all cases, using the Win RooF (version 
5.7, Mitani Corporation, osaka, Japan) software package. 
Images of microvessels were selected for clarity in each of 5 
high-power fields from each immunohistochemically stained 
specimen, using a CCD digital camera (DXM1200; Nikon, 
Melville, NY). The MVD was measured, and then averaged.
Statistical Analysis
The mean profile of A549/Mock-5 and that of A549/
Cap9 were graphically presented over time. To determine 
whether the means were significantly different at given time 
points after injection, we analyzed the average tumor vol-
umes determined after 40 days (days 41, 48, and 56) to sta-
bilize any variation in observations. After the tumor volumes 
of both A549/Mock-5 tumors and A549/Cap9 were obtained 
from each mouse, the average tumor volumes after day 40 
were compared using the paired t test. Distributions of aver-
aged MVD were demonstrated with box-plots and compared 
between NDRG1/Cap43-positve and -negative patients using 
the Wilcoxon rank-sum test. overall survival was defined as 
the time from surgery until the date of death resulting from 
any cause. The relationships between NDRG1/Cap43 expres-
sion and overall survival were examined by the Kaplan-
Meier method and the log-rank test. To evaluate the effect of 
NDRG1/Cap43 on overall survival with adjustment for pos-
sible confounding factors, Cox regression analysis was per-
formed. Differences were regarded as significant at p < 0.05 
unless otherwise indicated. Statistical analysis was performed 
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on the basis of histological type using SAS version 9.1 (SAS 
Institute Inc., Cary, NC) and R version 2.7.0.
RESULTS
Effects of NDRG1/Cap43 Knockdown on 
Expression of EGFR Family Proteins and Cell 
Proliferation in Human Lung Cancer Cells Are 
Not Consistent
To examine whether there are any correlations of expres-
sion between NDRG1/Cap43 and various growth factor recep-
tors, we examined the expression levels of NDRG1/Cap43 in 
relation to those of EGFR, HER2, HER3, and c-Met in eight 
NSCLC cell lines. Among these cell lines, LK87, QG56, and 
RERF-LC-AI showed relatively higher expression of NDRG1/
Cap43 than A549, whereas PC9, LC1, 11_18, and LC-Sq1 
showed relatively lower (about 30% or less) NDRG1/Cap43 
expression. The levels of HER2, HER3, and c-Met expression 
were decreased to various extents in LC1, 11_18, and LC-Sq1 
when the expression of NDRG1/Cap43 was relatively lower. 
By contrast, the expression of EGFR seemed to be relatively 
higher in PC9 and LC-Sq1 (Fig. 1A). However, an overall sur-
vey using Western blot analysis revealed no apparent correla-
tion between the level of NDRG1/Cap43 expression and that 
of various growth factor receptors.
We next examined the effect of NDRG1 knockdown 
using cognate siRNA on the expression of EGFR family pro-
teins and c-Met. Transient knockdown by transfection of A549 
cells with NDRG1 siRNA decreased the expression of HER2 
and HER3 by about 30 % to 50%, but changed the expression 
of EGFR and c-Met only negligibly (Fig. 1B and C). In QG56 
cells, NDRG1 knockdown markedly reduced the expression 
of EGFR, but did not affect the expression of HER2, HER3, 
and c-Met (Fig. 1B and C). Thus, in these two lung cancer 
cell lines, transient transfection with NDRG1/Cap43 siRNA 
did not induce consistent changes in the expression of growth 
factor receptors.
We next established stable NDRG1/Cap43-knockdown 
lung cancer cell lines by transfection of NDRG1 shRNA into 
both A549 and QG56. The resulting cell lines (A549/Sic-9 
and A549/Sic-11; QG56/Sic-2 and QG56/Sic-12) showed cell 
proliferation rates similar to those of their respective parental 
counterparts (Fig. 2A). A549/Sic-9 showed decreased HER3 
expression relative to A549/mock5, but no apparent changes 
in the expression of other growth factor receptors (Fig. 2B). 
By contrast, in another NDRG1/Cap43-knockdown cell line, 
the A549/Sic-11, expression of EGFR, but not that of other 
growth factor receptors, was specifically downregulated (Fig. 
2B). Conversely, relative to QG56/Mock2, the expression of 
HER3 in QG56/Sic-12 was increased, whereas that in QG56/
Sic-2 was similar. There were no apparent changes in the 
FIGURE 1. Lack of correlation 
between NDRG1/Cap43 expres-
sion level and expression of EGFR, 
HER2, HER3, and c-MET in human 
lung cancer. A, Expression of 
NDRG1/Cap43 in seven cell lines 
was determined by Western blot 
analysis in a human lung cancer 
cell line panel. B, A549 and QG56 
cells were treated with 25, 50, and 
100 nmol/l NDRG1 siRNA for 72 
hours, and the effects of NDRG1 
knockdown on expression of EGFR, 
HER2, HER3, and c-MET were evalu-
ated by Western blotting. NDRG1, 
N-myc downstream-regulated gene 
1; siRNA, Small interfering RNA.
783Copyright © 2012 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology  •  Volume  7, Number 5, May 2012 NDRG1/Cap43 is Correlated With Poor Prognosis in NSCLC
expression of other growth factors between QG56/Sic-2 and 
QG56/Sic-12 relative to those in QG56/Mock2 (Fig. 2B). Two 
NDRG1/Cap43 knockdown cell lines of A549 showed dif-
ferential effects on the expression of growth factor receptors 
including EGFR and HER3, suggesting the functional diver-
sity of NDRG1/Cap43 in lung cancer cells. However, there 
was no change in the cell proliferation rate between NDRG1/
Cap43 knockdowned cell lines and their parental counterpart. 
Furthermore, in A549 and QG56, there were no apparent 
changes in the expression of Akt, phospho-Akt (PAkt), extra-
cellular signal-regulated kinase (ERK), and phosphor-ERK 
(pERK) between NDRG1/Cap43-knockdown cell lines and 
mock cell lines. These data suggest that A549 and QG56 cells 
show no consistent changes in the expression of growth fac-
tor receptors resulting from NDRG1 knockdown, and also 
that altered expression of growth factor receptor by NDRG1 
knockdown does not affect cell proliferation.
NDRG1/Cap43 Knockdown Induces 
Downregulation of Angiogenic Factors and 
Tumor Angiogenesis
our previous studies revealed that overexpression of 
NDRG1/Cap43 suppresses tumor angiogenesis in pancreatic 
cancer, suggesting that NDRG1/Cap43 may be an angiogene-
sis-suppressor gene.13 However, in other human malignancies 
such as gastric cancer18 and cervical cancer,17 the NDRG1 over-
expression is inversely correlated with tumor angiogenesis. 
Therefore, NDRG1 may promote or suppress tumor angio-
genesis according to tumor type. Using the enzyme-linked 
immunosorbent assay, we compared the expression levels of 
two potent angiogenic factors, VEGF-A and IL-8/CXCL8, 
between NDRG1-knockdown cell lines and their parental 
counterparts (Fig. 3). All the NDRG1/Cap43-knockdown cell 
lines derived from A549 and QG56 showed significantly (p < 
0.05) reduced expression of VEGF-A and IL-8/CXCL8.
We then investigated whether NDRG1/Cap43 knock-
down using a xenograft assay system could modulate tumor 
growth in mice. The tumor growth rate of A549/Sic-9 cells 
in vivo was markedly reduced in comparison with the corre-
sponding mock-transfected line, A549/Mock-5 (Fig. 4A). The 
average tumor volume at day 40 differed significantly between 
A549/Sic-9 and A549/Mock-9 (p=0.0162). However, no in 
vivo tumor growth was evident for QG56/Sic-2, QG56/Sic-
12, and QG56/Mock2 cells (data not shown). We further com-
pared tumor angiogenesis between A549/Sic-9 tumors and 
A549/Mock9 tumors by IHC with anti-CD34 antibody (Fig. 
4B). A549/Sic-9 tumors showed less development of neoves-
sels than A549/Mock-5 tumors (Fig. 4B). Quantitative analy-
sis revealed a significant decrease in the number of MVD in 
A549/Sic-9 tumors by more than 50% relative to the control 
counterpart tumors (Fig. 4C).
We then investigated whether NDRG1 knockdown sup-
pressed angiogenesis by cancer cells in vivo using the dorsal 
air sac assay. Implantated A549/Mock5 cells developed thin 
FIGURE 2. Lack of effect of NDRG1 knockdown on cell proliferation in vitro. A, Comparison of cell growth between NDRG1 
siRNA transfectants and mock transfectants in A549 and QG56. Cell proliferation in RPMI 1640  containing 10% FBS was 
measured on days 1, 3, 5, and 7. Columns indicate mean values from three independent experiments; bars represent SD. B, 
Expression of NDRG1/Cap43 in NDRG1 siRNA transfectants or mock transfectants in two lung cancer cell lines determined by 
Western blot analysis. NDRG1, N-myc downstream-regulated gene 1; FBS, fetal bovine serum; siRNA, Small interfering RNA.
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and curled microvessels with tiny bleeding spots, in addition 
to the preexisting vessels (Fig. 4D), consistent with our previ-
ous study.24 By contrast, A549/Sic9 showed reduced develop-
ment of newly formed vessels. Quantitative analysis revealed a 
reduction of angiogenesis by about 60% in mice harboring the 
A549/Sic-9, as opposed to A549/Mock5, xenografts (Fig.4E).
Association of NDRG1 Expression with 
Angiogenesis, Clinicopathologic Characteristics, 
and Prognosis in NSCLC Patients
Using IHC analysis we examined whether the NDRG1/
Cap43 expression was associated with clinicopathologic fea-
tures in tissue samples from 182 patients with NSCLC. The 
tumor histology was classified as adenocarcinoma in 115 
patients and squamous cell carcinoma in 67. We scored the 
levels of NDRG1/Cap43 expression in the cytoplasm and 
nucleus, respectively, of cancer cells. Figure 5A and B shows 
representative examples of IHC staining for NDRG1/Cap43 
expression in the cytoplasm and nucleus of lung adenocarci-
noma and squamous cell carcinoma cells.
Nuclear NDRG1/Cap43 expression was positive in 102 
patients and negative in 80, whereas cytoplasmic NDRG1/
Cap43 expression was positive in 81 patients and negative 
in 101. In adenocarcinoma, NDRG1/Cap43 nuclear expres-
sion was positive in 44 patients and negative in 71, and cyto-
plasmic expression was positive in 64 and negative in 51. In 
squamous cell carcinoma, nuclear NDRG1/Cap43 expression 
was positive in 58 patients and negative in 9, and cytoplasmic 
NDRG1/Cap43 expression was positive in 37 patients and 
negative in 30.
Clinical and pathological characteristics of the 182 
patients analyzed in this study at diagnosis are summarized in 
Table 1. Results of Fisher’s exact test for association between 
molecular markers and NDRG1/Cap43 are shown in Table 1. 
In adenocarcinoma, there was a significant correlation between 
age and cytoplasmic NDRG1/Cap43 expression (p=0.0388), 
whereas there was no correlation between NDRG1 and sex, 
p-stage, and smoking status (Table 1). In squamous cell carci-
noma, none of the above factors were correlated with nuclear 
and cytoplasmic expression of NDRG1/Cap43. Cytoplasmic 
expression of NDRG1/Cap43 was significantly correlated 
with age in adenocarcinoma (p=0.0388), but not in squamous 
cell carcinoma (p=0.796). In adenocarcinoma, the ratio of the 
proportion of the highly expressed in the subgroup of age 65 
relative to that of age 64 was estimated at 0.62 (95%confi-
dence interval [CI] 0.41–0.97), indicating that NDRG1/Cap43 
in cytoplasm is likely to be less expressed in older patients. 
The Kaplan-Meier plots for overall survival in patients with 
high and low expression of nuclear NDRG1/Cap43 are shown 
for adenocarcinoma and squamous cell carcinoma in the left 
and right panels of Figure 5C, respectively. The survival curves 
differed significantly according to the expression of nuclear 
NDRG1/Cap43 in both adenocarcinoma (p=0.031; hazard 
ratio [HR]=1.70, 95%CI 1.05–2.78) and squamous cell car-
cinoma (p=0.034; HR=4.16, 95%CI 1.00–17.40). Conversely, 
the cytoplasmic expression of NDRG1/Cap43 was not associ-
ated with overall survival in either adenocarcinoma (p=0.637; 
HR=1.13, 95%CI 0.69–1.84) or squamous cell carcinoma 
(p=0.954; HR=1.02, 95%CI 0.55–1.90). To evaluate the effect 
of nuclear NDRG1/Cap43 on overall survival while adjusting 
for possible confounding factors, Cox regression analysis was 
performed for adenocarcinoma. No such analysis was per-
formed for squamous cell carcinoma because the number of 
patients showing high nuclear expression of NDRG1/Cap43 
was small. Estimated HRs are presented in Table 2. MVD, 
which is associated with expression of nuclear NDRG1/Cap43, 
was not strongly predictive of overall survival (p=0.692) 
(Fig. 6B). Contrary to this, even after adjustment for MVD 
and age, patients with high nuclear expression of NDRG1/
FIGURE 3. Effects of NDRG1/
Cap43 knockdown on expres-
sion of VEGF-A and IL-8/CXCL8. 
A and B Comparison of 24-hour 
VEGF-A and IL-8 protein production 
between NDRG1-knockdown cell 
lines and their parental counterpart 
by ELISA assay in A549 (A) and 
QG56 (B). Columns represent mean 
values from triplicate experiments; 
bars represent SD. *p < 0.05: 
Comparison between NDRG1/
Cap43 siRNA versus mock transfec-
tants. NDRG1, N-myc downstream-
regulated gene 1; VEGF-A, vascular 
endothelial growth factor-A; IL-8, 
interleukin-8; ELISA, enzyme-linked 
immunosorbent assay, siRNA, small 
interfering RNA.
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Cap43 had significantly shorter overall survival than those 
with low expression (p=0.0298; HR=1.76, 95% CI 1.06–2.92) 
(Table 2).
Association Between NDRG1/Cap43 
Expression and Tumor Angiogenesis in NSCLC
Finally, we examined whether NDRG1/Cap43 affected 
lung cancer angiogenesis in human patients. Tumor angiogen-
esis was evaluated by IHC analysis of clinical tumor samples 
using anti-CD34 antibody. Representative IHC images show-
ing high and low NDRG1/Cap43 expression are presented in 
Figure 6A.
Figure 6C shows the distributions of MVD using box-
plots according to the expression of nuclear NDRG1/Cap43. 
MVD was higher in adenocarcinoma than in squamous cell 
carcinoma. In patients with adenocarcinoma, the median MVD 
in patients with high expression of nuclear NDRG1/Cap43 
was 4370 (q1-q3:2924–7192) ,whereas that in patients with 
low expression was 2793 (q1-q3:2024–4216). In squamous 
cell carcinoma, the corresponding values in patients show-
ing high and low expression were 1146 (q1-q3:698–1505) 
and 731 (q1-q3:306–1035), respectively. In both adenocar-
cinoma (p=0.003) and squamous cell carcinoma (p=0.041), 
the difference in the median values was significantly higher 
in patients with high expression of nuclear NDRG1/Cap43 
than in patients with low expression (Fig. 6C). Expression 
of NDRG1/Cap43 in the cytoplasm was not associated with 
MVD in either adenocarcinoma or squamous cell carcinoma 
(data not shown).
FIGURE 4. Comparison of tumor growth and angiogenesis between NDRG1/Cap43 siRNA transfectants and corresponding 
mock transfectants. A, mean tumor volumes with SD for groups of A549/sic-9 or A549/Mock5 inoculated with 1 × 107 cells. 
Tumor volumes were determined every week. B, Representative photographs of tumor sections stained with anti-CD34 (micro-
vascular density) from A549/sic-9 and A549/Mock5. C, The mean microvessel densities for tumor sections from A549/sic-9 and 
A549/Mock5 were determined by counting the number of CD34-positive vessels in high-power fields of each section. Columns 
show mean values with SD from three independent experiments. D, Representative photographs of assay chambers contain-
ing NDRG1 siRNA transfectants and mock transfectants. E, The angiogenic responses were evaluated by counting the number 
of new blood vessels. Columns indicate mean values with SD from independents experiments. *p<0.05 significant difference 
between NDRG1 siRNA and mock transfectants. NDRG1, N-myc downstream-regulated gene 1; siRNA, small interfering RNA.
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DISCUSSION
IHC for NDRG1/Cap43 expression showed that NDRG1 
was expressed only negligibly in normal lung tissue, but was 
often expressed in either the nucleus or cytoplasm of cancer 
cells in both adenocarcinoma and squamous cell carcinoma 
(Fig. 5A, B, C). Quantitative analysis showed that among 
the various factors examined, the expression of NDRG1 
in the nucleus was significantly correlated with survival of 
NSCLC patients overall (p=0.0298), and also that of patients 
with adenocarcinoma (p=0.031) and squamous cell carci-
noma (0.034). NDRG1 expression in cancer cells is a predic-
tive marker of good outcome in patients with cancers of the 
prostate, breast, esophagus, colon, and pancreas, as well as 
neuroblastoma.13–16,29,30 By contrast, NDRG1 expression is 
a predictive marker of poor outcome in patients with liver, 
cervical, and gastric cancer.17–19 our present study indicated 
FIGURE 5. Expression of NDRG1/Cap43 in human lung cancer specimens analyzed by immunohistochemistry (IHC). A and B, 
Nuclear and cytoplasmic expression of NDRG1/Cap43 can be seen in the tumor cells of adenocarcinoma (A) and squamous cell 
carcinoma (B). C, Kaplan-Meier analysis of overall survival in relation to NDRG1/Cap43 expression levels for adenocarcinoma 
(Fig. 5C left) and squamous cell carcinoma (Fig. 5C right). NDRG1, N-myc downstream-regulated gene 1.
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that NDRG1 expression was predictive of poor outcome in 
patients with NSCLC. Collectively, the data suggest that the 
ability of NDRG1 expression to predict a good or poor out-
come depends upon the type of cancer. It still remains unclear 
why NDRG1/Cap43 could have a double-edged influence on 
cancer progression. NDRG1/Cap43 was originally isolated 
as a gene controlled by N-Myc and/or c-Myc. In some tumor 
types, NDRG1/Cap43 is strictly controlled by the Myc onco-
gene, whereas in others, it is not. The presence or absence of 
Myc-driven control of NDRG1/Cap43 seems to be different 
among tumor types. In contrast, in pancreas cancer cells, we 
have previously reported that NDRG1 is predictive of good 
prognosis, and also that NDRG1 suppresses tumor angiogen-
esis and growth through its inhibitory effect on the NF-kB 
pathway.13,31 Together, which signaling pathway including 
transcriptional factors could be activated or inactivated under 
the control of NDRG1 is also expected to be responsible for 
the double-edged function of NDRG1.
It has been shown that knockdown of NDRG1 does not 
alter the growth rates of human pancreas, prostate or colon can-
cer cells.13,32,33 Consistent with these findings, we showed here 
that the A549 and QG56 cell lines with NDRG1 knockdown 
had growth rates similar to those of their parental counterparts 
in culture. However, tumor growth in vivo was markedly 
decreased by NDRG1 knockdown in A549 cells, in compari-
son to the high growth rate of their parental counterpart cells. 
Thus NDRG1 downregulation seemed to specifically inhibit 
tumor growth in vivo but not during cell proliferation in vitro, 
suggesting a suppressive role of NDRG1/Cap43 against the 
development of neovessel tumor stroma by NSCLC cells. 
NDRG1 knockdown also suppressed production of the potent 
angiogenic factors VEGF and IL-8 by both types of human 
lung cancer cells, suggesting the involvement of reduced 
expression of such angiogenic factors in the poor angiogen-
esis resulting from NDRG1 knockdown. Conversely, NDRG1 
specifically suppressed the tumor angiogenesis and growth 
of pancreatic cancer cells, suggesting that NDRG1 is a puta-
tive angiogenesis-suppressor gene.13,31 In these previous stud-
ies, the expression of VEGF, IL-8 and other angiogenic CXC 
chemokines was markedly reduced in pancreatic cancer cells 
as a result of NDRG1 overexpression.13,31 Although it remains 
to be clarified how NDRG1 promotes or suppresses angiogen-
esis by cancer cells, the role of NDRG1 as an angiogenesis 
promoter or suppressor may depend upon tumor species or 
cancer cell type.
our previous study demonstrated for the first time that 
NDRG1/Cap43 overexpression markedly decreased tumor 
angiogenesis and tumor growth in mice bearing human pan-
creatic cancer xenografts. NDRG1 overexpression markedly 
reduced the expression of angiogenic factors such as VEGF, 
IL-8, and matrix metalloproteinase-9 in cultured pancreatic can-
cer cells.13,31 Consistent with in vitro and in vivo experimental 
results, IHC analysis also demonstrated an inverse correlation 
between NDRG1 expression and MVD in clinical samples from 
pancreatic cancer patients.13 However, our present study showed 
that NDRG1 exerted opposite effects on tumor angiogenesis 
TABLE 2. Multivariate Analysis of Overall Survival
p Value HR 95% CI
NDRG1/Cap43 (nucleus) High/Low 0.0298 1.757 1.057–2.922
Tumor angiogenesis (MVD) 0.6916 0.929 0.647–1.335
Age 0.6026 0.993 0.969–1.018
HR, hazard ratio; CI, confidence interval; NDRG1, N-myc downstream-regulated 
gene 1; MVD, microvascular density.
TABLE 1. Association of Nuclear and Cytoplasmic NDRG1/Cap43 Expression with Pathological Stage and Other Characteristics
Histological type Characteristics Number
NDRG1/Cap43 (nuclear) NDRG1/Cap43 (cyto)
Low High p value Low High p value
Adenocarcinoma N=115
Age −64 56 30 (53.60%) 26 (46.40%) 0.0877 19 (33.90%) 37 (66.10%) 0.0388
65− 59 41 (69.50%) 18 (30.50%) 32 (54.20%) 27 (45.80%)
Sex F 60 37 (61.70%) 23 (38.30%) 1 23 (38.30%) 37 (61.70%) 0.193
M 55 34 (61.80%) 21 (38.20%) 28 (50.90%) 27 (49.10%)
pStage I 44 27 (61.40%) 17 (38.60%) 0.7427 19 (43.20%) 25 (56.80%) 0.9304
II 19 10 (52.60%) 9 (47.40%) 8 (42.10%) 11 (57.90%)
III 36 23 (63.90%) 13 (36.10%) 17 (47.20%) 19 (52.80%)
Smoking status Never 62 39 (62.90%) 23 (37.10%) 0.8483 23 (37.10%) 39 (62.90%) 0.1316
Smoker 53 32 (60.40%) 21 (39.60%) 28 (52.80%) 25 (47.20%)
Squamous cell carcinoma N=67 Age −64 21 4 (19.00%) 17 (81.00%) 0.4458 10 (47.60%) 11 (52.40%) 0.7957
65− 46 5 (10.90%) 41 (89.10%) 20 (43.50%) 26 (56.50%)
Sex F 5 1 (20.00%) 4 (80.00%) 0.5255 2 (40.00%) 3 (60.00%) 1
M 62 8 (12.90%) 54 (87.10%) 28 (45.20%) 34 (54.80%)
pStage I 31 4 (12.90%) 27 (87.10%) 0.8087 13 (41.90%) 18 (58.10%) 0.949
II 16 3 (18.80%) 13 (81.30%) 8 (50.00%) 8 (50.00%)
III 20 2 (10.00%) 18 (90.00%) 9 (45.00%) 11 (55.00%)
Smoking status Never 4 1 (25.00%) 3 (75.00%) 0.4465 3 (75.00%) 1 (25.00%) 0.3179
Smoker 63 8 (12.70%) 55 (87.30%) 27 (42.90%) 36 (57.10%)
NDRG1, N-myc downstream-regulated gene 1.
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in the dorsal air sac assay and in clinical samples of NSCLC. 
Furthermore, in NSCLC, NDRG1/Cap43 was more predictive 
of higher tumor angiogenesis than of lower. A related study by 
Nishio et al.17 found that cervical cancers with higher NDRG1 
expression showed higher MVD, suggesting that NDRG1 
may promote angiogenesis in cervical cancer. Consistent with 
the positive correlation of NDRG1 with tumor angiogenesis, 
NDRG1 expression also showed a significant correlation with 
tumor angiogenesis or poor prognosis in patients with gastric 
cancer.18 Together, the data suggest that NDRG1 expression is 
predictive of tumor angiogenesis in lung cancer, as is the case 
in cervical and gastric cancer.
In conclusion, we have shown that NDRG1 is differ-
entially expressed in the cytoplasm and nucleus of NSCLC 
cells, but exhibits a close mutual association, suggesting that 
expression of NDRG1 in the nucleus parallels that in the cyto-
plasm. of the many biomarkers that are already known to pre-
dict poor prognosis of lung cancer, NDRG1 will be potentially 
applicable as a novel biomarker of prognosis in its close asso-
ciation with tumor angiogenesis, and might be useful for 
development of new diagnosis for malignant progression in 
patients with NSCLC.
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